中文名稱

SARS-CoV-2 (COVID-19) Alpha Variant (B.1.1.7, UK) Spike S1 (RBD) 重組蛋白

英文名字

SARS-CoV-2 (COVID-19) Alpha Variant (B.1.1.7, UK) Spike S1 (RBD) Recombinant Protein

供應商

ProSci

產品貨號

PSI-21-808

產品報價

￥詢價/50ug

產品說明書

點擊查看

購買方式

銀行轉賬、電匯、支票、現金，在線支付寶及網銀支付，或直接與我們電話聯系400-6800-868

產品新聞

背景資料

SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.

The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells. Recently, a more transmissible variant of SARS-CoV-2, called B.1.1.7, was detected in the south of England. This variant carries a mutation in the RBD at the position 501 (N501Y).

序列

Receptor-binding domain (RBD) of SARS-CoV-2 Spike protein S1 (aa 319-541) containing the mutation N501Y is fused to the N-terminus of the Fc region of human IgG1.

來源宿主

HEK293 細胞

溶解建議

艾美捷溫馨提示:開蓋前,請先離心。廠家建議您，按照該貨號產品的說明書中要求的方式進行溶解和使用。

保存建議

Short Term StorageL: +4°C, Long Term Storage: -20°C, Handling Advice: After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. For maximum product recovery after thawing, centrifuge the vial before opening the cap. Use/Stability: Stable for at least 6 months after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.

其他

ProSci Incorporated于1998年成立于美國加州圣地亞哥市,從事抗體等科研試劑的研發、生產和銷售。產品涵蓋了細胞凋亡、信號轉導、免疫、腫瘤、細胞生物、神經生物、傳染病等領域。ProSci擁有超過30000種單克隆抗體和多克隆抗體。ProSci的抗體大都經免疫親和層析純化,具有高純度、高親和力、特異性強等特點,所有的ProSci抗體都經過了嚴格的驗證測試和質量控制,已保證高質量的產品。此外,ProSci還提供標記二抗,重組蛋白,細胞和組織裂解液,細胞涂片,組織切片,多肽等產品與抗體配套使用。

注意

該頁面的中文產品信息的翻譯，僅供參考。準確的產品信息請以廠家的英文說明書為準。下單前，請瀏覽說明書確認。

分享到：